Search Results
Showing Results for trials,
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
We are delighted to share the latest issue of touchREVIEWS in Ophthalmology, showcasing a diverse range of articles that highlight the innovation, interdisciplinary collaboration and continued advances driving progress in eye care today. We begin this issue with an important ...
On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov ...
The FDA has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME). Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME while requiring fewer treatments than standard-of-care eye injections.
4D Molecular Therapeutics, a clinical-stage genetic medicines company, has announced promising topline interim results from Part 1 of the SPECTRA clinical trial evaluating 4D-150, a novel treatment for diabetic macular edema (DME).
The uvea is a vascular stratum that includes the iris, ciliary body and choroid. Uveitis is defined as inflammation of a part of the uvea or its entirety, but it is also used to describe inflammatory processes of any part ...
Thermoreceptors on the ocular surface play a critical role in the development of dry eye disease (DED). An experimental eye drop called AR-15512, which activates cooling receptors, has been found to provide fast and continuous relief from dry eye symptoms, ...
The EURETINA 2024 Congress, held in Barcelona from September 19-22, brought together leading experts in ophthalmology to share the latest research and innovative treatments for retinal diseases. Among the highlights were several late-breaking abstracts that showcased promising advances in therapeutics for conditions such as retinopathy of prematurity (ROP), diabetic retinopathy (DR) and age-related macular degeneration (AMD). These studies not only demonstrated the efficacy and safety of novel treatment options but also addressed critical unmet needs in reducing patient burden and improving long-term outcomes.
A recent study published in Ophthalmology demonstrates the effectiveness of oral antioxidant and lutein/zeaxanthin supplements in slowing the progression of geographic atrophy (GA) associated with age-related macular degeneration (AMD).
We are pleased to present the latest edition of touchREVIEWS in Ophthalmology. In this issue, we offer a series of engaging editorials, in-depth review articles and insightful original research highlighting some of the latest breakthroughs, innovations and practical insights in ...
Age-related macular degeneration (AMD) is a chronic deterioration and dysfunction of the outer retinal tissue and Bruch’s membrane (BrM). It is the leading cause of vision loss in people older than 60 years and is estimated to affect 288 million people ...
Thyroid eye disease (TED) is an autoimmune condition that can lead to significant visual impairment, facial disfigurement and decreased quality of life. It affects 16 out of every 100,000 females and 2.9 out of every 100,000 males. Risk factors for TED include age, female ...
Contrast sensitivity (CS), which is an important element of functional vision, helps in differentiating an object from its background. CS affects several aspects of vision, such as acuity, dark adaptation, visual field, motion detection and pattern recognition.1 A decline in ...
Neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME) are two leading causes of visual impairment and blindness in the USA.1,2 Faricimab is the first bispecific antibody approved by the US Food and Drug Administration in ophthalmology and was ...
The accumulation of transudative fluid in the suprachoroidal space, known as choroidal effusion, is a prevalent and often asymptomatic complication of glaucoma surgery. Choroidal effusions have also been linked with other aetiologies, including infections, inflammatory diseases, medications and other ocular ...
Age-related macular degeneration (AMD) is one of the main causes of irreversible vision loss in ageing populations worldwide.1 In 2019, the US recorded 1.49 million people aged 40 years or older with late-stage AMD, reflecting a crude prevalence rate of 0.94%.2 Geographic atrophy (GA), ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
